Member Info for PhilBanks

I would like to view the contents obviously, but such a price is absurd. Also its 2018 Outlook, and I rather feel that rene has probably already completely changed the outlook for the foreseeable future with the results it's announced in H1 2019.

Yeah I think Maifesto is correct, they have to report even if they continue buying/selling, but the point is they have a few days to actually report it:

'The notification to the issuer shall be effected as soon as possible, but not later than four trading days in the case of a non-UKissuer and two trading days in all other cases, after the date on which the relevant person:

(1) learns of the acquisition or disposal or of the possibility of exercising voting rights, or on which, having regard to the circumstances, should have learned of it, regardless of the date on which the acquisition, disposal or possibility of exercising voting rights takes effect; or
(2) is informed about the event mentioned in DTR 5.1.2 R (2).
And for the purposes of (1) above a person shall, in relation to a transaction to which he is a party or which he has instructed, be deemed to have knowledge of the acquisition, disposal or possibility to exercise voting rights no later than two trading days following the transaction in question and where a transaction is conditional upon the approval by public authorities of the transaction or on a future uncertain event the occurrence of which is outside the control of the parties to the agreement, the parties are deemed to have knowledge of the acquisition, disposal or possibility of exercising voting rights only when the relevant approvals are obtained or when the event happens.'

So 2 trading days if domestic, or 4 if overseas. So I make that either by the end of today, or the end of Monday.

Think the TR-1s holding RNS's can take a few days before they have to be announced to market. Not entirely certain on timescales, but should be end of this week at the latest. Could also be woodford buying more though, in which case a threshold may not have been crossed and no rns necessary.

It's 3.44% of the total shares in issue, so an rns will reveal all in coming days. Agree with the points earlier though, it will have taken a long time to fill that order, and consequently the share price would not have risen over the last few sessions if that was a sell, it would defy logic.... Although this is AIM, which at times does seem like an alternate reality.

Community chest: banker's error in your favour; buy as many sxx shares as you want for 13p and sell them for 17p.

Wow - that's a fair chunk!

Not sure how many people on here get excited about charts and technical analysis, but it's beginning to look good for some movement in my opinion. Support established and tested at 15p. RSI moving out of overbought territory and also critically showing a bullish divergence from last time it tested 15p. Momentum changing I would suggest.

There's almost certainly no foundation to it, but you can't help but wonder why someone would trade a single share for £2.87p, when the commission would cost them a tenner or thereabouts.

A 1 share trade just went through, maybe the wait is over! Unless of course there is no foundation to that theory....

True. However not sure on the exact protocol for announcing the results. As we know for cohort 1 they released the results to the market on the day they were presenting at the conference, so clearly that must have been acceptable in regulatory terms.

Yes an update can't be far off. However, I think it has previously been stated that the results from the 2nd cohort of phase 2a will be announced at a conference. Looking at the events page on the website, there are no upcoming conferences schedule that rene are presenting at.

Not sure if posted already today, but looks like some good news:

https://www.linkedin.com/feed/update/urn:li:activity:6536535611556409344

Hopefully the link works, let me know if not.

Bought some the other day and I'm intending on gradually building up a decent holding here. Looks to have good potential and seemingly under the radar if this forum is anything to go by.

The spread is pretty large though, so this could put some investors off. Fundamentals looks strong nonetheless

With small companies like this, drip feeding of news is important in maintaining investor interest and sentiment. I would be very surprised if they didn't announce the results from the next cohort as and when they are available - furthermore, would they not have a regulatory requirement to do this as its price sensitive information?

Notable by his absence. Very much doubt he would have sold though - think he has the highest expectations for this share from anyone here. He was posting a couple of days.... Could always have been banned for a few days for something he said on a different board

Would give me a wry smile to think that a patient whose vision has miraculously returned following treatment with hRPC has logged onto their broker for the first time in years and gladly filled their boots with shares purchased from their own insider knowledge! Who could blame them!!

Also just done a little reading on that. 'significant' is apparently typically defined as information that may lead to a 10% change in share price, as a rule of thumb. Perhaps the timing of the last buys (ie not long before the release of the rns regarding the 2nd follow up of phase 2a cohort 1) was not seen as significant under that definition? Had it been the first follow up, then clearly this would have been considered significant.

.... Or my date estimations could be off and the follow up had not taken place at that point, and thus no inside information was 'officially' available to the directors.

Yes, not sure how directors were allowed to purchase at that time with results from the follow-up basically known within the company at that time (most likely, IMO). Whether this is a story of history repeating itself, we'll know in the coming days!

Presumably the directors who purchased will have had the all clear from the legal people with regards to timings etc. Anyone with greater knowledge of the regulatory requirements care to clarify the matter?

From my post on 3rd May:

'Made a little spreadsheet to try and work out the approximate timings of follow-ups and results. I struggled to find a definitive start date for the treatment of the 1st patient of cohort 1 (of Phase 2a), but believe it to be around the middle of Dec 2018.

Based on the timings of various announcements, I estimate patients 2 and 3 were treated around 27th Jan 2019, with the first follow-up around the 13th Feb 2019 and the results announced to the market on the 20th Feb 2019. The second follow up was around the 14th April 2019, with the results announced on the 26th April 2019.

We know the 2nd cohort of patients (of Phase 2a) began treatment around the 18th March 2019, so by my reckoning the first follow-up should be around 17th May 2019, with the results reported around 24th to 27th May 2019. Obviously a few assumptions built in here, but should hopefully be getting an RNS in around 3 weeks, or by the end of May at the latest.'

Big buys that you mention today align with when I expected first follow-up to be for the 2nd cohort of Phase 2a. Could even get a director deal RNS after hours, who knows?

Yeah, despite what I said about technical analysis the other day, I can't argue that the bull flag isn't looking absolutely textbook.